Blood cancers
32 public biotech companies we cover are developing treatments for leukemia, lymphoma, myeloma and related cancers. 20 upcoming catalysts are listed below, with dates as the companies gave them.
Companies
- Acrivon Therapeutics (ACRV)Thesis Intact
Acute myeloid leukemia
- Actinium Pharmaceuticals (ATNM)Thesis Challenged
B-cell malignancies, Non-Hodgkin lymphoma, Acute myeloid leukemia, Myelodysplastic syndrome
- Adaptive Biotechnologies (ADPT)Thesis Challenged
Multiple myeloma, Mantle cell lymphoma, Cutaneous t cell lymphoma, Chronic lymphocytic leukemia, and 2 more
- ADC Therapeutics SA (ADCT)Thesis Challenged
Follicular lymphoma, Marginal zone lymphoma, Diffuse large B-cell lymphoma
- Agios Pharmaceuticals (AGIO)Thesis Challenged
Polycythemia vera
- Artiva Biotherapeutics (ARTV)Thesis Intact
Hematologic cancers
- Ascentage Pharma Group Internat (AAPG)Thesis Intact
CLL/SLL, B-cell lymphoma, Multiple myeloma, B-cell malignancies, and 11 more
- Atara Biotherapeutics (ATRA)Thesis Challenged
EBV+ PTLD, Post-transplant lymphoproliferative disease
- Autolus Therapeutics (AUTL)Thesis Intact
B-cell non-Hodgkin lymphoma, Acute lymphoblastic leukemia
- C4 Therapeutics (CCCC)Thesis Intact
Multiple myeloma
- Cardiff Oncology (CRDF)Thesis Challenged
Chronic myelomonocytic leukemia
- Cartesian Therapeutics (RNAC)Thesis Intact
Multiple myeloma
- Cellectar Biosciences (CLRB)Thesis Challenged
Waldenstrom Macroglobulinemia, Waldenström macroglobulinemia
- Compass Therapeutics (CMPX)Thesis Challenged
Hodgkin lymphoma
- Corvus Pharmaceuticals (CRVS)Thesis Intact
Peripheral T-cell lymphoma, Autoimmune lymphoproliferative syndrome
- CRISPR Therapeutics (CRSP)Thesis Intact
Follicular lymphoma, Marginal zone lymphoma, Relapsed or refractory b-cell malignancies
- Cullinan Therapeutics (CGEM)Thesis Intact
Acute myeloid leukemia
- Evaxion (EVAX)Thesis Intact
Acute myeloid leukemia
- ImmunityBio (IBRX)Thesis Intact
Non-Hodgkin lymphoma
- Karyopharm Therapeutics (KPTI)Thesis Challenged
Myelofibrosis, Multiple myeloma, Diffuse large b-cell lymphoma
- Keros Therapeutics (KROS)Thesis Intact
Myelofibrosis, Myelodysplastic syndromes
- Moleculin Biotech (MBRX)Thesis Challenged
Acute myeloid leukemia
- Nektar Therapeutics (NKTR)Thesis Intact
Large b-cell lymphoma
- NextCure (NXTC)Thesis Broken
Acute myeloid leukemia
- Omeros (OMER)Thesis Challenged
Acute myeloid leukemia
- ORIC Pharmaceuticals (ORIC)Thesis Intact
Multiple myeloma
- Precision BioSciences (DTIL)Thesis Intact
Diffuse large b-cell lymphoma
- Recursion Pharmaceuticals (RXRX)Thesis Intact
Lymphoma, B cell malignancies, Hematologic malignancies
- Sana Biotechnology (SANA)Thesis Challenged
Multiple myeloma, Non-Hodgkin lymphoma
- SELLAS Life Sciences Group (SLS)Thesis Intact
Multiple myeloma, Acute myeloid leukemia, Peripheral t-cell lymphoma, Acute lymphoblastic leukemia
- Silence Therapeutics (SLN)Thesis Intact
Polycythemia vera, Myelodysplastic syndrome
- TScan Therapeutics (TCRX)Thesis Challenged
Hematologic malignancies
Drug pages
Upcoming catalysts
Firm dates · a specific day set by the company or regulator
Later
- Mar 31in 157 daysTabelecleucel · FDA decision · EBV+ PTLD · ≥1 prior therapy
Estimated timing · a month, quarter, half-year or year-end the company gave
Expected in December 2026
- December 2026CLN-049 · Phase 1 results · Relapsed/refractory AML · MDS
Expected in Q4 2026
- Q4 2026ZYNLONTA · Phase 1b final results (LOTIS-7) · Diffuse large B-cell lymphoma · relapsed/refractory
- Q4 2026Selinexor · sNDA accepted for review · Myelofibrosis
- Q4 2026SLS009 · Phase 2 topline results · Acute myeloid leukemia · newly diagnosed first-line
- Q4 2026TSC-101 · Phase 1 interim results (ALLOHA) · Hematologic malignancies · post-HCT
Expected in H2 2026
- H2 2026AG-236 · Phase 2 start · Polycythemia vera
- H2 2026Tabelecleucel · BLA resubmission · EBV+ PTLD · post-SOT/HCT
- H2 2026Selinexor · Phase 3 topline results (XPORT-MM-031) · Multiple myeloma · anti-CD38 pre-treated
Expected by end of 2026
- before end of 2026EVX-04 · Regulatory submission · Acute myeloid leukemia
- As early as 2026SG293 · Phase 1 results · Non-Hodgkin lymphoma
Expected in Q1 2027
- Q1 2027Annamycin · Phase 2/3 results (MIRACLE) · Acute myeloid leukemia · relapsed/refractory
Expected by end of March 2027
- early 2027Iopofosine I-131 · Phase 3 start · Waldenstrom Macroglobulinemia · post-BTKi refractory
Expected in Q2 2027
- Q2 2027ZYNLONTA · Phase 2 results · Follicular lymphoma · relapsed/refractory
- Q2 2027TSC-101 · Phase 1 long-term results (ALLOHA) · Hematologic malignancies · post-HCT
Expected in H1 2027
- H1 2027ACR-7280 · IND submission · Acute myeloid leukemia
- H1 2027REC-3565 · Phase 1 interim results (EXCELERIZE) · B cell malignancies
- H1 2027Divesiran · Phase 3 start · Polycythemia vera
Expected by end of June 2027
- mid-2027Cemsidomide · Phase 1b interim results · Multiple myeloma · earlier lines
- Mid-2027SG227 · Phase 1 start · Multiple myeloma